Evelien Schaafsma
Overview
Explore the profile of Evelien Schaafsma including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
499
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sajani A, Schaafsma E, Croteau W, ElTanbouly M, Nowak E, Cheng C, et al.
Res Sq
. 2025 Jan;
PMID: 39866877
While naïve CD4 T cells have historically been considered a homogenous population, recent studies have provided evidence that functional heterogeneity exists within this population. Using single cell RNA sequencing (scRNAseq),...
2.
Sergent P, Pinto-Cardenas J, Carrillo A, Davalos D, Perez M, Lechuga D, et al.
Cells
. 2024 Sep;
13(17.
PMID: 39273048
Neoadjuvant intratumoral (IT) therapy could amplify the weak responses to checkpoint blockade therapy observed in breast cancer (BC). In this study, we administered neoadjuvant IT anti-canine PD-1 therapy (IT acPD-1)...
3.
Valdivia G, Alonso-Miguel D, Perez-Alenza M, Zimmermann A, Schaafsma E, Kolling 4th F, et al.
Cells
. 2023 Sep;
12(18).
PMID: 37759464
The lack of optimal models to evaluate novel agents is delaying the development of effective immunotherapies against human breast cancer (BC). In this prospective open label study, we applied neoadjuvant...
4.
Li C, Zhang B, Schaafsma E, Reuben A, Wang L, Turk M, et al.
Cell Rep Med
. 2023 Jul;
4(7):101121.
PMID: 37467716
Determining the prognostic association of different immune cell types in the tumor microenvironment is critical for understanding cancer biology and developing new therapeutic strategies. However, this is challenging in certain...
5.
Yao K, Zhou E, Schaafsma E, Zhang B, Cheng C
Cancer Med
. 2022 Nov;
12(5):5590-5602.
PMID: 36394080
Background: Immune checkpoint proteins play critical functions during the immune response to cancer and have been targeted by immune checkpoint blockade therapy. V-domain Ig suppressor of T cell activation (VSIR)...
6.
Schaafsma E, Croteau W, ElTanbouly M, Nowak E, Smits N, Deng J, et al.
Cancer Immunol Res
. 2022 Oct;
11(1):38-55.
PMID: 36260656
V domain immunoglobulin suppressor of T-cell activation (VISTA) is a premier target for cancer treatment due to its broad expression in many cancer types and enhanced expression upon development of...
7.
Schaafsma E, Jiang C, Nguyen T, Zhu K, Cheng C
Cancers (Basel)
. 2022 Oct;
14(19).
PMID: 36230719
Gliomas make up ~80% of malignant brain tumors in adults and are responsible for the majority of deaths from primary brain tumors. The glioma tumor microenvironment (TME) is a dynamic,...
8.
Yao K, Schaafsma E, Zhang B, Cheng C
PLoS Comput Biol
. 2022 Mar;
18(3):e1009495.
PMID: 35263321
Although estrogen-receptor-positive (ER+) breast cancer is generally associated with favorable prognosis, clinical outcome varies substantially among patients. Genomic assays have been developed and applied to predict patient prognosis for personalized...
9.
Jiang C, Schaafsma E, Hong W, Zhao Y, Zhu K, Chao C, et al.
Front Immunol
. 2022 Feb;
12:703821.
PMID: 35111147
Background: Neoantigens are presented on the cancer cell surface by peptide-restricted human leukocyte antigen (HLA) proteins and can subsequently activate cognate T cells. It has been hypothesized that the observed...
10.
Schaafsma E, Takacs E, Kaur S, Cheng C, Kurokawa M
Sci Rep
. 2022 Jan;
12(1):1317.
PMID: 35079034
The tumor suppressor p53, encoded by the TP53 gene, is mutated or nullified in nearly 50% of human cancers. It has long been debated whether TP53 mutations can be utilized...